TY - JOUR
T1 - The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC)
T2 - Results of a multicenter prospective study
AU - Nakagawa, Kazuo
AU - Asamura, Hisao
AU - Tsuta, Koji
AU - Nagai, Kanji
AU - Yamada, Eiji
AU - Ishii, Genichiro
AU - Mitsudomi, Tetsuya
AU - Ito, Akihiko
AU - Higashiyama, Masahiko
AU - Tomita, Yasuhiko
AU - Inoue, Masayoshi
AU - Morii, Eiichi
AU - Matsuura, Nariaki
AU - Okumura, Meinoshin
N1 - Funding Information:
Sysmex Corporation (Kobe, Japan) provided research funding for this multicenter prospective study. Sysmex had no role in the data interpretation or preparation of the report. The authors report no conflicts of interest. We thank the entire staff of the clinical and pathologic laboratories at the participating institutes and Sysmex Corporation (Hayato Niiro and Daiki Kobayashi) for their technical support.
Publisher Copyright:
© 2016 Elsevier Ireland Ltd.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objectives: The precise and rapid diagnosis of the presence or absence of lymph node (LN) metastasis is essential for deciding upon an appropriate therapeutic strategy for patients with non-small cell lung cancer (NSCLC). We conducted a prospective multicenter clinical trial in Japan to evaluate a rapid, automated and objective assay system, the one-step nucleic acid amplification (OSNA) assay (Sysmex Corp), which targets cytokeratin 19 mRNA, to detect LN metastasis of NSCLC. Materials and methods: A total of 410 Lymph nodes (LNs) from 111 patients with clinical stage IB to IIIA NSCLC who underwent lung resection with LN dissection were included in this study. The LNs were divided into 4 blocks and examined by either the OSNA assay or a 3-level histological examination. The results of each method were compared and further analyses were performed for discordant cases. The primary endpoint was a concordance rate of more than 85% between the two methods. Results: The concordance rate between the two methods was 92.7% (95% CI, 89.7-95.0%), with a sensitivity of 79.7% (95% CI, 67.2-89.0%). Discordant results were observed in 30 LNs (5.8%), and were mainly due to a tissue allocation bias and/or contamination by CK19-expressing alveolar cells in LNs. Conclusion: The OSNA assay gave a diagnosis that was as accurate as a 3-level histological examination, which is more detailed than a histological examination in routine clinical practice. The OSNA assay might be useful in intraoperative decision-making in personalized lung cancer surgery based on the LN status.
AB - Objectives: The precise and rapid diagnosis of the presence or absence of lymph node (LN) metastasis is essential for deciding upon an appropriate therapeutic strategy for patients with non-small cell lung cancer (NSCLC). We conducted a prospective multicenter clinical trial in Japan to evaluate a rapid, automated and objective assay system, the one-step nucleic acid amplification (OSNA) assay (Sysmex Corp), which targets cytokeratin 19 mRNA, to detect LN metastasis of NSCLC. Materials and methods: A total of 410 Lymph nodes (LNs) from 111 patients with clinical stage IB to IIIA NSCLC who underwent lung resection with LN dissection were included in this study. The LNs were divided into 4 blocks and examined by either the OSNA assay or a 3-level histological examination. The results of each method were compared and further analyses were performed for discordant cases. The primary endpoint was a concordance rate of more than 85% between the two methods. Results: The concordance rate between the two methods was 92.7% (95% CI, 89.7-95.0%), with a sensitivity of 79.7% (95% CI, 67.2-89.0%). Discordant results were observed in 30 LNs (5.8%), and were mainly due to a tissue allocation bias and/or contamination by CK19-expressing alveolar cells in LNs. Conclusion: The OSNA assay gave a diagnosis that was as accurate as a 3-level histological examination, which is more detailed than a histological examination in routine clinical practice. The OSNA assay might be useful in intraoperative decision-making in personalized lung cancer surgery based on the LN status.
KW - Histological examination
KW - LN status
KW - Lymph node metastasis
KW - Non-small cell lung cancer (NSCLC)
KW - One-step nucleic acid amplification (OSNA)
UR - http://www.scopus.com/inward/record.url?scp=84963553265&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963553265&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2016.03.015
DO - 10.1016/j.lungcan.2016.03.015
M3 - Article
C2 - 27237020
AN - SCOPUS:84963553265
VL - 97
SP - 1
EP - 7
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
ER -
